Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

Neuroscience

Volumn 144, Issue 3, 2007, Pages 950-960

  Wilcock, D M ^a   Jantzen, P T ^a   Li, Q ^a   Morgan, D ^a   Gordon, M N ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; cerebral amyloid angiopathy; immunotherapy; inflammation; microglia

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; NCX 2216; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN 1; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING DISORDER; CELL ACTIVATION; COMPARATIVE STUDY; CONTROLLED STUDY; IMMUNOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PARENCHYMAL AMYLOID; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; DRUG THERAPY, COMBINATION; FLURBIPROFEN; METABOLIC CLEARANCE RATE; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRESENILIN-1; SENILE PLAQUES; TREATMENT OUTCOME; VACCINATION;

EID: 33845904135     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.10.020     Document Type: Article

References (42)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyama I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging 21 (2000) 383-421
2. Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110 (2005) 345-359
3. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med 6 (2000) 916-919
4. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., and Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 100 (2003) 2023-2028
5. Bernado A., Gasparini L., Ongini E., and Minghetti L. Dynamic regulation of microglial functions by the non-steroidal anti-inflammatory drug NCX 2216: Implications for chronic treatments of neurodegenerative diseases. Neurobiol Dis 22 (2006) 25-32
6. 1-42 immune-mediated therapies. Neurobiol Aging 24 (2003) 969-976
7. Deane R., Sagare A., Hamm K., Parisi M., LaRue B., Guo H., Wu Z., Holtzman D.M., and Zlokovic B.V. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25 (2005) 11495-11503
8. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98 (2001) 8850-8855
9. 1-42 peptide. DNA Cell Biol 20 (2001) 723-729
10. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refelo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
11. Ferrer I., Boada R., Sanchez M., Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14 (2004) 11-20
12. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.W., Hope C.E., Hatcher J.M., DiCarlo G., Gottschall P.E., Morgan D., and Arendash G.W. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging 22 (2001) 377-385
13. Gordon M.N., Holcomb L.A., Jantzen P.T., DiCarlo G., Wilcock D., Boyett K.W., Connor K., Melachrino J., O'Callaghan J.P., and Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1 + APP mouse. Exp Neurol 173 (2002) 183-195
14. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
15. 1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
16. Herber D.L., Roth L.M., Wilson D., Wilson N., Mason J.E., Morgan D., and Gordon M.N. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 190 (2004) 245-253
17. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., and Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4 (1998) 97-100
18. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
19. James D.S. The multisystem adverse effects of NSAID therapy. J Am Osteopath Assoc 99 (1999) S1-S7
20. Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola D., Morgan D., and Gordon M.N. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22 (2002) 2246-2254
21. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T.J., Nixon P.A., Mercken M., Bergeron C., Fraser P.E., St. George-Hislop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
22. Li Q., Cao C., Chackerian B., Schiller J., Gordon M., Ugen K.E., and Morgan D. Overcoming antigen masking of anti-amyloid beta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloid beta immunized amyloid precursor protein transgenic mice. BMC Neurosci 5 (2004) 21
23. Mackenzie I.R., and Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50 (1998) 986-990
24. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., and Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
25. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M.N., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
26. Morgan D., Gordon M.N., Tan J., Wilcock D., and Rojiani A.M. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64 (2005) 743-753
27. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2003) 448-452
28. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
29. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., and Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
30. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., and DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25 (2005) 629-636
31. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103 (2006) 443-448
32. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
33. Seabrook T.J., Jiang L., Thomas K., and Lemere C.A. Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. J Neuroinflammation 3 (2006) 14
34. Seabrook T.J., Bloom J.K., Iglesias M., Spooner E.T., Walsh D.M., and Lemere C.A. Species-specific immune response to immunization with human versus rodent A beta peptide. Neurobiol Aging 25 (2004) 1141-1151
35. Solomon B., Koppel R., Frenkel D., and Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed monoclonal antibodies. Proc Natl Acad Sci U S A 94 (1997) 4109-4112
36. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., and Goodman S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 4 (2004) 159-169
37. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., and Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
38. Wilcock D.M., Gordon M.N., Ugen K.E., Gottschall P.E., DiCarlo G., Dickey C., Boyett K.W., Jantzen P.T., Connor K.E., Melachrino J., Hardy J., and Morgan D. Number of Aβ inoculations in APP + PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 20 (2001) 731-736
39. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., and Morgan D. Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms independent of and associated with microglial activation. J Neurosci 213 (2003) 3745-3751
40. Wilcock D.M., Muniredddy S.K., Rosenthal A., Ugen K.E., Gordon M.N., and Morgan D. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiol Dis 15 (2004) 11-20
41. Wilcock D.M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., Wilson D., Wilson N., Freeman M.J., Gordon M.N., and Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24 (2004) 6144-6151
42. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., and Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 8 (2004) 24